The effect of omega 3 polyunsaturated fatty acid supplementation on inflammatory markers and insulin resistanse factors in patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Phase 2

• Conditions: Condition 1: type 2 diabetes. Condition 2: Nonalcoholic fatty liver disease (NAFLD).; Non-insulin-dependent diabetes mellitus; Fatty (change of) liver, not elsewhere classified (NAFLD)

• Registration Number: IRCT2017103030489N2
• Lead Sponsor: Yazd Shahid Sadoughi University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Inclusion criteria include type II diabetes, nonalcoholic fatty liver disease, non-participation in the intervention program, ranging in age from 18 to 60 years, both men and women, not using insulin therapy, without any kidney; liver heart; thyroid, bleeding disorders or malignancies and lack of special diet Exclusion criteria from the study: type1 diabetes,alcoholic fatty liver disease, hepatitis type B and C, abuse alcohol, consume drugs and blood thinners such as warfarin, heparin or pentoxifylline, who recently had surgery, having allergic to seafood, uncontrolled high blood pressure, a weakened immune system and use drugs that cause fatty liver, such as steroids, estrogen, amiodarone, tamoxifen in the last 6 months

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting Insulin serum. Timepoint: baseline and after 12 weeks. Method of measurement: ELISA.;TNF-a. Timepoint: baseline and after 12 weeks. Method of measurement: ELISA.;IL-6. Timepoint: baseline and after 12 weeks. Method of measurement: ELISA.;Hs-CRP. Timepoint: baseline and after 12 weeks. Method of measurement: By Laboratory Kit.;HOMA-IR. Timepoint: baseline and after 12 weeks. Method of measurement: Blood Sampling and putting glucose and insulin levels in formula.;HOMA-ß. Timepoint: baseline and after 12 weeks. Method of measurement: Blood Sampling and putting glucose and insulin levels in formula.;QUICKI. Timepoint: baseline and after 12 weeks. Method of measurement: formula calculation.;Beta cell function. Timepoint: baseline and after 12 weeks. Method of measurement: HOMA2 calculator software.